COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID
31/01/2024
Retrospective observational study of electronic medical records of more than 90 million people living in the U.S. Long COVID shares symptoms with chronic overlapping pain disorders like fibromyalgia and appears [...]
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
31/01/2024
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein [...]
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
31/01/2024
TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it [...]
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
31/01/2024
SUNNYVALE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular [...]
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
31/01/2024
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease ( [...]
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
31/01/2024
Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer 1 Fast Track [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
31/01/2024
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Half-year report
31/01/2024
DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results [...]
BioSenic provides support to forthcoming European conference on graft-versus-host disease
31/01/2024
Mont-Saint-Guibert, Belgium, January 31, 2024, 7.00 am CEST – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, [...]
BioSenic soutient la prochaine conférence européenne sur la maladie du greffon contre l'hôte
31/01/2024
Mont-Saint-Guibert, Belgique, le 31 janvier 2024, à 7h00 CEST – BIOSENIC ( Euronext Bruxelles et Paris : BIOS) , société spécialisée en essais cliniques dans les maladies auto-immunes et inflammatoires graves et la [...]
Release date of annual report 2023 for ALK and webcast
31/01/2024
On Thursday, 8 February 2024 in the afternoon, ALK ( ALKB:DC / OMX: ALK B / AKBLF ) releases its annual report for 2023. ALK will host an online meeting for analysts and institutional investors that day at 4.00pm (CET) [...]
Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting
31/01/2024
Company announcement, Helsinki, 31 January 2024 at 10 AM (EET) Nexstim Plc: Proposals of the Shareholder’s Nomination Board to the Annual General Meeting The Shareholder’s Nomination Board of Nexstim Corporation (NXTMH: [...]
LifeArc makes multi-million pound investment to support drug discovery in sub-Saharan Africa
31/01/2024
LifeArc makes multi-million pound investment to support drug discovery in sub-Saharan Africa LifeArc and the Bill & Melinda Gates Foundation are jointly investing £6 million ($7.2m) to enhance drug discovery [...]
Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
31/01/2024
Bagsværd, Denmark, 31 January 2024 - Financial report for the period 1 January 2023 to 31 December 2023 Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion [...]
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
31/01/2024
Press Release Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA ® January 31, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA [...]
Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostene bunod commercialisé sous le nom de VYZULTA®
31/01/2024
Communiqué de presse Nicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostène bunod commercialisé sous le nom de VYZULTA ® 31 janvier 2024 – diffusion à 7h30 Sophia Antipolis, France [...]
ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
31/01/2024
ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry ANT-01 is in late-stage development as an adjunctive treatment for major depressive disorder ( [...]
Geneva Court Grants Temporary Moratorium to ObsEva
31/01/2024
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today [...]
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
31/01/2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and [...]

Pages